慢性粒细胞白血病进展期治疗策略的研究进展  

Progress of treatment strategies for advanced stages of chronic myeloid leukemia

作　　者：谷晨曦 赵慧芳 宋永平[2] 张龑莉 Gu Chenxi;Zhao Huifang;Song Yongping;Zhang Yanli(Department of Hematology,Affiliated Cancer Hospital of Zhengzhou University,Zhengzhou 450003,China;Department of Hematology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)

机构地区：[1]郑州大学附属肿瘤医院血液科,郑州450003 [2]郑州大学第一附属医院血液科,郑州450052

出　　处：《白血病．淋巴瘤》2024年第8期501-505,共5页Journal of Leukemia & Lymphoma

摘　　要：慢性粒细胞白血病(CML)是一种克隆性血液系统恶性肿瘤。近年来, 其治疗主要是应用酪氨酸激酶抑制剂(TKI)靶向BCR::ABL融合基因, 部分患者在应用TKI期间发生耐药或药物不耐受并进入进展期(包括加速期和急变期)。文章对新型TKI药物、TKI联合治疗方案以及其他靶点药物在进展期CML治疗中的研究进展进行综述。Chronic myeloid leukemia(CML)is a clonal hematologic malignancy.In recent years,its treatment mainly involves the application of tyrosine kinase inhibitors(TKI)targeting the BCR:ABL fusion gene,but some patients still develop drug resistance or drug intolerance during TKI treatment and enter into the advanced stages(include accelerated phase and blast crisis phase).This article reviews the research progress of novel TKI drugs,TKI combined regimens and other targeted drugs for treatment ofadvanced stages of CML.

关 键 词：白血病 髓系 慢性 BCR-ABL阳性 融合蛋白质类 BCR-ABL 酪氨酸激酶抑制剂 分子靶向疗法 

分 类 号：R733.72[医药卫生—肿瘤]